To achieve systemic infection, bacterial pathogens must overcome the critical and challenging step of transmigration across epithelial barriers. This is particularly true for opportunistic pathogens such as Pseudomonas aeruginosa, an agent which causes nosocomial infections. Despite extensive study, details on the mechanisms used by this bacterium to transmigrate across epithelial tissues, as well as the entry sites it uses, remain speculative. Here, using real-time microscopy and a model epithelial barrier, we show that P. aeruginosa employs a paracellular transmigration route, taking advantage of altered cell-cell junctions at sites of cell division or when senescent cells are expelled from the cell layer. Once a bacterium transmigrates, it is followed by a cohort of bacteria using the same entry point. The basal compartment is then invaded radially from the initial penetration site. Effective transmigration and propagation require type 4 pili, the type 3 secretion system (T3SS) and a flagellum, although flagellum-deficient bacteria can occasionally invade the basal compartment from wounded areas. In the basal compartment, the bacteria inject the T3SS toxins into host cells, disrupting the cytoskeleton and focal contacts to allow their progression under the cells. Thus, P. aeruginosa exploits intrinsic host cell processes to breach the epithelium and invade the subcellular compartment.
References
[1]
Gellatly SL, Hancock RE. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathogens and disease. 2013;67(3):159–73. doi: 10.1111/2049-632X.12033 pmid:23620179.
[2]
Ramphal R, Small PM, Shands JW Jr., Fischlschweiger W, Small PA Jr. Adherence of Pseudomonas aeruginosa to tracheal cells injured by influenza infection or by endotracheal intubation. Infection and immunity. 1980;27(2):614–9. pmid:6769805; PubMed Central PMCID: PMCPMC550808.
[3]
de Bentzmann S, Roger P, Puchelle E. Pseudomonas aeruginosa adherence to remodelling respiratory epithelium. The European respiratory journal. 1996;9(10):2145–50. pmid:8902481. doi: 10.1183/09031936.96.09102145
[4]
Fleiszig SM, Evans DJ, Do N, Vallas V, Shin S, Mostov KE. Epithelial cell polarity affects susceptibility to Pseudomonas aeruginosa invasion and cytotoxicity. Infection and immunity. 1997;65(7):2861–7. pmid:9199460; PubMed Central PMCID: PMC175402.
[5]
Lee A, Chow D, Haus B, Tseng W, Evans D, Fleiszig S, et al. Airway epithelial tight junctions and binding and cytotoxicity of Pseudomonas aeruginosa. The American journal of physiology. 1999;277(1 Pt 1):L204–17. pmid:10409249.
[6]
Heiniger RW, Winther-Larsen HC, Pickles RJ, Koomey M, Wolfgang MC. Infection of human mucosal tissue by Pseudomonas aeruginosa requires sequential and mutually dependent virulence factors and a novel pilus-associated adhesin. Cellular microbiology. 2010;12(8):1158–73. doi: 10.1111/j.1462-5822.2010.01461.x pmid:20331639; PubMed Central PMCID: PMC2906647.
[7]
Soong G, Parker D, Magargee M, Prince AS. The type III toxins of Pseudomonas aeruginosa disrupt epithelial barrier function. Journal of bacteriology. 2008;190(8):2814–21. pmid:18165298. doi: 10.1128/JB.01567-07.
[8]
Deng Q, Barbieri JT. Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins. Annual review of microbiology. 2008;62:271–88. pmid:18785839. doi: 10.1146/annurev.micro.62.081307.162848.
[9]
Hauser AR. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nature reviews. 2009;7(9):654–65. pmid:19680249. doi: 10.1038/nrmicro2199.
[10]
El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H. Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Critical care medicine. 2012;40(4):1157–63. pmid:22080633. doi: 10.1097/CCM.0b013e3182377906.
[11]
Hauser AR, Cobb E, Bodi M, Mariscal D, Valles J, Engel JN, et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Critical care medicine. 2002;30(3):521–8. pmid:11990909. doi: 10.1097/00003246-200203000-00005
[12]
Le Berre R, Nguyen S, Nowak E, Kipnis E, Pierre M, Quenee L, et al. Relative contribution of three main virulence factors in Pseudomonas aeruginosa pneumonia. Critical care medicine. 2011;39(9):2113–20. doi: 10.1097/CCM.0b013e31821e899f pmid:21572326.
[13]
Vance RE, Rietsch A, Mekalanos JJ. Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo. Infection and immunity. 2005;73(3):1706–13. pmid:15731071. doi: 10.1128/iai.73.3.1706-1713.2005
[14]
Rangel SM, Diaz MH, Knoten CA, Zhang A, Hauser AR. The Role of ExoS in Dissemination of Pseudomonas aeruginosa during Pneumonia. PLoS pathogens. 2015;11(6):e1004945. doi: 10.1371/journal.ppat.1004945 pmid:26090668; PubMed Central PMCID: PMCPMC4474835.
[15]
Murray TS, Ledizet M, Kazmierczak BI. Swarming motility, secretion of type 3 effectors and biofilm formation phenotypes exhibited within a large cohort of Pseudomonas aeruginosa clinical isolates. Journal of medical microbiology. 2010;59(Pt 5):511–20. doi: 10.1099/jmm.0.017715-0
[16]
Feldman M, Bryan R, Rajan S, Scheffler L, Brunnert S, Tang H, et al. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infection and immunity. 1998;66(1):43–51. pmid:9423837; PubMed Central PMCID: PMC107856.
[17]
Mattick JS. Type IV pili and twitching motility. Annual review of microbiology. 2002;56:289–314. doi: 10.1146/annurev.micro.56.012302.160938 pmid:12142488.
[18]
Hayashi N, Nishizawa H, Kitao S, Deguchi S, Nakamura T, Fujimoto A, et al. Pseudomonas aeruginosa injects type III effector ExoS into epithelial cells through the function of type IV pili. FEBS letters. 2015;589(8):890–6. doi: 10.1016/j.febslet.2015.02.031 pmid:25747138.
[19]
Bucior I, Pielage JF, Engel JN. Pseudomonas aeruginosa pili and flagella mediate distinct binding and signaling events at the apical and basolateral surface of airway epithelium. PLoS pathogens. 2012;8(4):e1002616. doi: 10.1371/journal.ppat.1002616 pmid:22496644; PubMed Central PMCID: PMC3320588.
[20]
Kierbel A, Gassama-Diagne A, Rocha C, Radoshevich L, Olson J, Mostov K, et al. Pseudomonas aeruginosa exploits a PIP3-dependent pathway to transform apical into basolateral membrane. The Journal of cell biology. 2007;177(1):21–7. pmid:17403925. doi: 10.1083/jcb.200605142
[21]
Kierbel A, Gassama-Diagne A, Mostov K, Engel JN. The phosphoinositol-3-kinase-protein kinase B/Akt pathway is critical for Pseudomonas aeruginosa strain PAK internalization. Molecular biology of the cell. 2005;16(5):2577–85. pmid:15772151. doi: 10.1091/mbc.e04-08-0717
[22]
Apodaca G, Bomsel M, Lindstedt R, Engel J, Frank D, Mostov KE, et al. Characterization of Pseudomonas aeruginosa-induced MDCK cell injury: glycosylation-defective host cells are resistant to bacterial killing. Infection and immunity. 1995;63(4):1541–51. pmid:7890421; PubMed Central PMCID: PMCPMC173187.
[23]
Bucior I, Mostov K, Engel JN. Pseudomonas aeruginosa-mediated damage requires distinct receptors at the apical and basolateral surfaces of the polarized epithelium. Infection and immunity. 2010;78(3):939–53. pmid:20008530. doi: 10.1128/IAI.01215-09.
[24]
Dacheux D, Goure J, Chabert J, Usson Y, Attree I. Pore-forming activity of type III system-secreted proteins leads to oncosis of Pseudomonas aeruginosa-infected macrophages. Molecular microbiology. 2001;40(1):76–85. pmid:11298277. doi: 10.1046/j.1365-2958.2001.02368.x
[25]
Fraylick JE, La Rocque JR, Vincent TS, Olson JC. Independent and coordinate effects of ADP-ribosyltransferase and GTPase-activating activities of exoenzyme S on HT-29 epithelial cell function. Infection and immunity. 2001;69(9):5318–28. pmid:11500401. doi: 10.1128/iai.69.9.5318-5328.2001
[26]
Huber P, Bouillot S, Elsen S, Attree I. Sequential inactivation of Rho GTPases and Lim kinase by Pseudomonas aeruginosa toxins ExoS and ExoT leads to endothelial monolayer breakdown. Cell Mol Life Sci. 2014;71(10):1927–41. doi: 10.1007/s00018-013-1451-9 pmid:23974244.
[27]
Kazmierczak BI, Engel JN. Pseudomonas aeruginosa ExoT acts in vivo as a GTPase-activating protein for RhoA, Rac1, and Cdc42. Infection and immunity. 2002;70(4):2198–205. pmid:11895987. doi: 10.1128/iai.70.4.2198-2205.2002
[28]
Krall R, Schmidt G, Aktories K, Barbieri JT. Pseudomonas aeruginosa ExoT is a Rho GTPase-activating protein. Infection and immunity. 2000;68(10):6066–8. pmid:10992524. doi: 10.1128/iai.68.10.6066-6068.2000
[29]
Pentecost M, Otto G, Theriot JA, Amieva MR. Listeria monocytogenes invades the epithelial junctions at sites of cell extrusion. PLoS pathogens. 2006;2(1):e3. doi: 10.1371/journal.ppat.0020003 pmid:16446782; PubMed Central PMCID: PMC1354196.
[30]
Verove J, Bernarde C, Bohn YS, Boulay F, Rabiet MJ, Attree I, et al. Injection of Pseudomonas aeruginosa Exo toxins into host cells can be modulated by host factors at the level of translocon assembly and/or activity. PloS one. 2012;7(1):e30488. pmid:22299042. doi: 10.1371/journal.pone.0030488.
[31]
Gloag ES, Turnbull L, Huang A, Vallotton P, Wang H, Nolan LM, et al. Self-organization of bacterial biofilms is facilitated by extracellular DNA. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(28):11541–6. doi: 10.1073/pnas.1218898110 pmid:23798445; PubMed Central PMCID: PMC3710876.
[32]
Join-Lambert O, Morand PC, Carbonnelle E, Coureuil M, Bille E, Bourdoulous S, et al. Mechanisms of meningeal invasion by a bacterial extracellular pathogen, the example of Neisseria meningitidis. Progress in neurobiology. 2010;91(2):130–9. doi: 10.1016/j.pneurobio.2009.12.004 pmid:20026234.
[33]
Kwong MS, Evans DJ, Ni M, Cowell BA, Fleiszig SM. Human tear fluid protects against Pseudomonas aeruginosa keratitis in a murine experimental model. Infection and immunity. 2007;75(5):2325–32. doi: 10.1128/IAI.01404-06 pmid:17325054; PubMed Central PMCID: PMC1865794.
[34]
Sana TG, Hachani A, Bucior I, Soscia C, Garvis S, Termine E, et al. The second type VI secretion system of Pseudomonas aeruginosa strain PAO1 is regulated by quorum sensing and Fur and modulates internalization in epithelial cells. The Journal of biological chemistry. 2012;287(32):27095–105. doi: 10.1074/jbc.M112.376368 pmid:22665491; PubMed Central PMCID: PMC3411052.
[35]
Schaible B, McClean S, Selfridge A, Broquet A, Asehnoune K, Taylor CT, et al. Hypoxia modulates infection of epithelial cells by Pseudomonas aeruginosa. PloS one. 2013;8(2):e56491. doi: 10.1371/journal.pone.0056491 pmid:23418576; PubMed Central PMCID: PMC3572047.
[36]
Tran CS, Rangel SM, Almblad H, Kierbel A, Givskov M, Tolker-Nielsen T, et al. The Pseudomonas aeruginosa type III translocon is required for biofilm formation at the epithelial barrier. PLoS pathogens. 2014;10(11):e1004479. doi: 10.1371/journal.ppat.1004479 pmid:25375398; PubMed Central PMCID: PMC4223071.
[37]
Chi E, Mehl T, Nunn D, Lory S. Interaction of Pseudomonas aeruginosa with A549 pneumocyte cells. Infection and immunity. 1991;59(3):822–8. pmid:1671777; PubMed Central PMCID: PMC258333.
[38]
Emam A, Carter WG, Lingwood C. Glycolipid-Dependent, Protease Sensitive Internalization of Pseudomonas aeruginosa Into Cultured Human Respiratory Epithelial Cells. The open microbiology journal. 2010;4:106–15. doi: 10.2174/1874285801004010106 pmid:21270937; PubMed Central PMCID: PMC3026333.
[39]
Fleiszig SM, Zaidi TS, Fletcher EL, Preston MJ, Pier GB. Pseudomonas aeruginosa invades corneal epithelial cells during experimental infection. Infection and immunity. 1994;62(8):3485–93. pmid:8039920; PubMed Central PMCID: PMC302982.
[40]
Clark CA, Thomas LK, Azghani AO. Inhibition of protein kinase C attenuates Pseudomonas aeruginosa elastase-induced epithelial barrier disruption. American journal of respiratory cell and molecular biology. 2011;45(6):1263–71. doi: 10.1165/rcmb.2010-0459OC pmid:21757681.
[41]
Golovkine G, Faudry E, Bouillot S, Voulhoux R, Attree I, Huber P. VE-cadherin cleavage by LasB protease from Pseudomonas aeruginosa facilitates type III secretion system toxicity in endothelial cells. PLoS pathogens. 2014;10(3):e1003939. doi: 10.1371/journal.ppat.1003939 pmid:24626230; PubMed Central PMCID: PMC3953407.
[42]
Nomura K, Obata K, Keira T, Miyata R, Hirakawa S, Takano K, et al. Pseudomonas aeruginosa elastase causes transient disruption of tight junctions and downregulation of PAR-2 in human nasal epithelial cells. Respiratory research. 2014;15:21. doi: 10.1186/1465-9921-15-21 pmid:24548792; PubMed Central PMCID: PMC3936699.
[43]
Bojarski C, Weiske J, Schoneberg T, Schroder W, Mankertz J, Schulzke JD, et al. The specific fates of tight junction proteins in apoptotic epithelial cells. Journal of cell science. 2004;117(Pt 10):2097–107. doi: 10.1242/jcs.01071 pmid:15054114.
[44]
Keller SH, Nigam SK. Biochemical processing of E-cadherin under cellular stress. Biochemical and biophysical research communications. 2003;307(2):215–23. pmid:12859942. doi: 10.1016/s0006-291x(03)01143-4
[45]
Schmeiser K, Grand RJ. The fate of E- and P-cadherin during the early stages of apoptosis. Cell death and differentiation. 1999;6(4):377–86. doi: 10.1038/sj.cdd.4400504 pmid:10381631.
[46]
Steinhusen U, Weiske J, Badock V, Tauber R, Bommert K, Huber O. Cleavage and shedding of E-cadherin after induction of apoptosis. The Journal of biological chemistry. 2001;276(7):4972–80. doi: 10.1074/jbc.M006102200 pmid:11076937.
[47]
Guillot L, Nathan N, Tabary O, Thouvenin G, Le Rouzic P, Corvol H, et al. Alveolar epithelial cells: master regulators of lung homeostasis. The international journal of biochemistry & cell biology. 2013;45(11):2568–73. doi: 10.1016/j.biocel.2013.08.009 pmid:23988571.
[48]
Uhal BD. Cell cycle kinetics in the alveolar epithelium. The American journal of physiology. 1997;272(6 Pt 1):L1031–45. pmid:9227501.
[49]
Doran KS, Banerjee A, Disson O, Lecuit M. Concepts and mechanisms: crossing host barriers. Cold Spring Harb Perspect Med. 2013;3:a010090. doi: 10.1101/cshperspect.a010090. pmid:23818514
[50]
Dacheux D. Mise en évidence et étude de la cytotoxicité de Pseudomonas aeruginosa envers les neutrophiles humains. [PhD thesis]2000.
[51]
Dacheux D, Attree I, Schneider C, Toussaint B. Cell death of human polymorphonuclear neutrophils induced by a Pseudomonas aeruginosa cystic fibrosis isolate requires a functional type III secretion system. Infection and immunity. 1999;67(11):6164–7. pmid:10531282; PubMed Central PMCID: PMC97008.
[52]
Pastor A, Chabert J, Louwagie M, Garin J, Attree I. PscF is a major component of the Pseudomonas aeruginosa type III secretion needle. FEMS microbiology letters. 2005;253(1):95–101. pmid:16239085. doi: 10.1016/j.femsle.2005.09.028
